Details of the Drug

General Information of Drug (ID: DMMPSA1)

Drug Name
Tusamitamab ravtansine
Synonyms SAR408701
Indication
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25 Phase 3 [1]
Aggressive cancer 2A00-2F9Z Phase 2 [2]
Breast cancer 2C60-2C65 Phase 2 [2]
Gastric cancer 2B72 Phase 2 [3]
Drug Type
Antibody drug conjugate
Cross-matching ID
TTD ID
D2D6NJ
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Carcinoembryonic antigen CEA (CD66e) TTY6DTE CEAM5_HUMAN Not Available [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Non-small-cell lung cancer
ICD Disease Classification 2C25
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Carcinoembryonic antigen CEA (CD66e) DTT CEACAM5 4.49E-01 -2.02E-03 -0.08
Carcinoembryonic antigen CEA (CD66e) DTT CEACAM5 2.23E-05 -0.56 -2.16
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05245071) Open-label, Phase 2 Study, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine in Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT04659603) Open-label, Multi-cohort, Phase 2 Trial, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine (SAR408701) Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors. U.S.National Institutes of Health.
3 ClinicalTrials.gov (NCT05703555) INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701. U.S.National Institutes of Health.
4 Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. Ann Oncol. 2022 Apr;33(4):416-425.